CD14 and acute myeloid leukemia: To assess the cause of the reduction in viable cells in response to revumenib exposure over time in the KMT2A-rearranged AML cell lines NOMO-1, MONO-MAC-1, and SHI-1 (Figure 2A), we conducted apoptosis, cell cycle, and myeloid differentiation CD14/CD117 FACS assays on day 7 and day 14.